LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Well being Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Well being” or the “Firm”), proclaims that it has entered in the present day into an settlement (the “Gross sales Settlement”) with Jefferies LLC (“Jefferies”) pursuant to which the Firm might now and again sooner or later promote, by way of at-the-market distributions with Jefferies performing as gross sales agent, such frequent shares as would have an mixture supply worth of as much as US$50.zero million, together with gross sales made straight on the Nasdaq World Market (“Nasdaq”) or on another present buying and selling marketplace for the frequent shares in the USA. No frequent shares will likely be provided or bought in Canada.
The Firm has filed a prospectus complement (the “Complement”) dated December 23, 2020 and a brief type base shelf prospectus dated December 23, 2020 (the “Base Prospectus”) and in the USA pursuant to a registration assertion on Kind F-10, which was declared efficient by the U.S. Securities and Trade Fee (the “SEC”) on December 23, 2020 (the “Registration Assertion”), in accordance with the Multijurisdictional Disclosure System established between Canada and the USA.
Copies of the Complement and accompanying Base Prospectus could also be obtained by contacting Jefferies LLC, Consideration: Fairness Syndicate Prospectus Division, 520 Madison Avenue, 2nd Ground, New York, NY 10022, by phone at 877-821-7388 or by electronic mail at firstname.lastname@example.org. The Gross sales Settlement, the Complement and the accompanying Base Prospectus can be discovered on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
BELLUS Well being’s frequent shares are dual-listed on the Nasdaq and the Toronto Inventory Trade (“TSX”) beneath the buying and selling image “BLU”. For the needs of the TSX approval, the Firm relied on the exemption set forth in Part 602.1 of the Guide, which gives that the TSX is not going to apply its requirements to sure transactions involving eligible interlisted issuers on a acknowledged alternate, reminiscent of Nasdaq.
This information launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase, nor shall there be any sale of those securities in any province, state or jurisdiction wherein such supply, solicitation or sale can be illegal previous to the registration or qualification beneath the securities legal guidelines of any such province, state or jurisdiction.
About BELLUS Well being
BELLUS Well being is a clinical-stage biopharmaceutical firm growing novel therapeutics for the remedy of persistent cough and different hypersensitization-related problems. The Firm’s product candidate, BLU-5937, is being developed for the remedy of persistent cough and persistent pruritus.
Cautionary Observe Concerning Ahead-Wanting Statements
Sure statements contained on this information launch might represent “forward-looking statements” inside the that means of relevant securities legal guidelines, together with statements about gross sales of frequent shares pursuant to the Gross sales Settlement. Such statements, primarily based as they’re on the present expectations of administration, inherently contain quite a few necessary dangers, uncertainties and assumptions, identified and unknown. Nevertheless, they shouldn’t be considered a illustration that any of the plans will likely be achieved. Precise future occasions might differ from the anticipated occasions expressed in such forward-looking statements. BELLUS Well being believes that expectations represented by forward-looking statements are affordable, but there might be no assurance that such expectations will show to be right. The reader mustn’t place undue reliance, if any, on any forward-looking statements included on this information launch. These forward-looking statements converse solely as of the date made, and BELLUS Well being is beneath no obligation and disavows any intention to replace publicly or revise such statements on account of any new data, future occasion, circumstances or in any other case, except required by relevant securities legal guidelines.